Background: The purpose of this study was to determine the prognostic significance of the maximumstandardized uptake value (SUVmax) on F-18-fluorodeoxyglucose (FDG)-positron emission tomography (PET)in patients undergoing surgical treatment for non-small cell lung cancer. Materials and Methods: Seventy-eightconsecutive patients (58 with adenocarcinomas, 20 with squamous cell carcinomas) treated with potentiallycurative surgery were retrospectively reviewed. Results: The SUVmax was significantly higher in the patientswith recurrent than with non-recurrent adenocarcinoma (p<0.01). However, among the patients with squamouscell carcinoma, there were no differences with or without recurrence (p=0.69). Multivariate analysis indicatedthat the SUVmax of adenocarcinoma lesions was a significant predictor of disease-free survival (p=0.04). Inaddition, an SUVmax of 6.19, the cut-off point based on ROC curve analysis of the patients with pathological IBor more advanced stage adenocarcinomas, was found to be a significant predictor of disease-free survival (p<0.01). Conclusions: SUVmax is a useful predictor of disease-free survival in patients with resected adenocarcinoma, butnot squamous cell carcinoma. Patients with adenocarcinoma exhibiting an SUVmax above 6.19 are candidatesfor more intensive adjuvant therapy.
(2014). Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma. Asian Pacific Journal of Cancer Prevention, 15(23), 10171-10174.
MLA
. "Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma". Asian Pacific Journal of Cancer Prevention, 15, 23, 2014, 10171-10174.
HARVARD
(2014). 'Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma', Asian Pacific Journal of Cancer Prevention, 15(23), pp. 10171-10174.
VANCOUVER
Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma. Asian Pacific Journal of Cancer Prevention, 2014; 15(23): 10171-10174.